Management of Muscle Relaxation With Rocuronium and Reversal With Neostigmine or Sugammadex Guided by Quantitative Neuromuscular Monitoring

Stephan R Thilen; James R Sherpa; Adrienne M James; Kevin C Cain; Miriam M Treggiari; Sanjay M Bhananker

doi:10.1213/ANE.0000000000006511

Management of Muscle Relaxation With Rocuronium and Reversal With Neostigmine or Sugammadex Guided by Quantitative Neuromuscular Monitoring

Anesth Analg. 2023 May 12. doi: 10.1213/ANE.0000000000006511. Online ahead of print.

Authors

Stephan R Thilen¹, James R Sherpa², Adrienne M James¹, Kevin C Cain³, Miriam M Treggiari⁴, Sanjay M Bhananker¹

Affiliations

¹ From the Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.
² School of Medicine, University of Washington, Seattle, Washington.
³ Department of Biostatistics, University of Washington School of Public Health, Seattle, Washington.
⁴ Department of Anesthesiology, Duke University, Durham, North Carolina.

PMID: 37171989
DOI: 10.1213/ANE.0000000000006511

Abstract

Background: The optimal pharmacological reversal strategy for neuromuscular blockade remains undefined even in the setting of strong recommendations for quantitative neuromuscular monitoring by several national and international anesthesiology societies. We evaluated a protocol for managing rocuronium blockade and reversal, using quantitative monitoring to guide choice of reversal agent and to confirm full reversal before extubation.

Methods: We conducted a prospective cohort study and enrolled 200 patients scheduled for elective surgery involving the intraoperative use of rocuronium. Providers were asked to adhere to a protocol that was similar to local practice recommendations for neuromusculalr block reversal that had been used for >2 years; the protocol added quantitative monitoring that had not previously been routinely used at our institution. In this study, providers used electromyography-based quantitative monitoring. Pharmacological reversal was accomplished with neostigmine if the train-of-four (TOF) ratio was 0.40 to 0.89 and with sugammadex for deeper levels of blockade. The primary end point was the incidence of postoperative residual neuromuscular blockade (PRNB), defined as TOF ratio <0.9 at time of extubation. We further evaluated the difference in pharmacy costs had all patients been treated with sugammadex.

Results: A total of 189 patients completed the study: 66 patients (35%) were reversed with neostigmine, 90 patients (48%) with sugammadex, and 33 (17%) patients recovered spontaneously without pharmacological reversal. The overall incidence of residual paralysis was 0% (95% CI, 0-1.9). The total acquisition cost for all reversal drugs was United States dollar (USD) 11,358 (USD 60 per patient) while the cost would have been USD 19,312 (USD 103 per patient, 70% higher) if sugammadex had been used in all patients.

Conclusions: A protocol that includes quantitative monitoring to guide reversal with neostigmine or sugammadex and to confirm TOF ratio ≥0.9 before extubation resulted in the complete prevention of PRNB. With current pricing of drugs, the selective use of sugammadex reduced the total cost of reversal drugs compared to the projected cost associated with routine use of sugammadex for all patients.

Trial registration: ClinicalTrials.gov NCT03958201.

Associated data

ClinicalTrials.gov/NCT03958201